Most “risky” assets have rallied sharply since the US election last week, and today’s news about progress towards a vaccine for COVID-19 has given them a further boost. While it is hard to judge just how long-lasting the effects of either development will prove, both arguably point to further gains in risky assets against a backdrop of a recovering global economy and continued support from policymakers.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to gain:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services